<DOC>
	<DOCNO>NCT00669461</DOCNO>
	<brief_summary>Delayed colonic transient time secondary multi-degenerative process likely cause constipation idiopathic PD . Since lubiprostone demonstrate ability accelerate colonic transit time healthy volunteer addition activate chloride channel intestinal cell , potential improve constipation patient PD subsequent adverse event control neurological manifestation PD . So hypothesize following : 1 . Lubiprostone improve rating Bristol stool form scale ( BSFS ) patient PD induce constipation compare baseline . ( primary ) 2 . Lubiprostone increase number spontaneous bowel movement ( SBM ) per week , compare baseline . ( secondary ) 3 . Lubiprostone improve health relate quality life subject PD induce constipation . ( secondary )</brief_summary>
	<brief_title>Lubiprostone Treatment Constipation Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>1 . Age 5085 year 2 . Diagnosis Parkinson 's disease 3 . Constipation define Rome III committee 4 . BSFS equal 1 less equal 3 5 . Normal colonoscopy last 5 year ( normal define absence obstructive lesion colon ) 6 . All woman subject post menopausal surgically sterile . 1 . Known hypersensitivity reaction Amitiza ( Lubiprostone ) 2 . Known significant adverse effect previous treatment Lubiprostone include ; new worsen abdominal pain , severe diarrhea , nausea , vomit , severe headache . 3 . Renal dysfunction creatinine clearance le 15 ml/min 4 . Abnormal liver enzymes history chronic liver disorder 5 . History bowel obstruction , , abdominal adhesion . 6 . Abnormal Colonoscopy ( obstructive lesion within colon ) 7 . Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>